Healogix plays a role in $350M Bayhill – Genentech dealPrint this Page

Paul Westberg, VP of Business Development for Bayhill Therapeutics, wrote
“I am pleased to say that all of the hard work by everyone who has contributed to the program, including Healogix, has resulted in a premier partnership with Genentech / Roche. Thanks for all of your recent work on this project.”
Click here┬áto view an article “Bayhill Therapeutics Snags $350M Deal with Genentech” in BioWorld Today.